CAMBRIDGE, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, ...

Company will host investor conference call and webcast tomorrow, December 24 at 8:00 a.m. ET CAMBRIDGE, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (AGIO), a commercial-stage ...

Aqvesme is expected to be available in late January 2026. The Food and Drug Administration (FDA) has approved Aqvesme™ (mitapivat) for the treatment of anemia in adults with alpha- or beta-thalassemia ...

Pyrukynd (mitapivat) is a prescription drug that’s used to treat hemolytic anemia. Pyrukynd comes as an oral tablet. Pyrukynd is used to treat hemolytic anemia in adults who have pyruvate kinase (PK) ...

– Prespecified Statistical Criterion for the Primary Endpoint in ACTIVATE-KidsT Was Not Met; Results Were Clinically Meaningful, with Observed Response Rates Higher for Mitapivat than Placebo for the ...

The FDA approved mitapivat (Aqvesme) as a disease-modifying treatment for anemia in adults with alpha- or beta-thalassemia, a rare inherited blood disease that affects hemoglobin production. An oral ...

– Results from Phase 3 ENERGIZE-T Study of Mitapivat in Transfusion-dependent Thalassemia will be Presented in Oral Session – – Tebapivat Phase 1 Data in Sickle Cell Disease and Phase 2b ...

A significantly greater percentage of patients treated with mitapivat achieved hemoglobin response compared with those who received placebo. Topline results were announced from a phase 3 trial ...

Agios Pharmaceuticals Inc.’s fourth-quarter and full-year 2023 financial report in mid-February highlighted further prospects with Pyrukynd (mitapivat), the pyruvate kinase activator for hemolytic ...

Shares of Agios Pharmaceuticals AGIO have plunged 23% over the past six months, primarily due to pipeline and regulatory ...

Lindsay Curtis is a health & medical writer in South Florida. She worked as a communications professional for health nonprofits and the University of Toronto’s Faculty of Medicine and Faculty of ...

Hemolytic anemia occurs when red blood cells are destroyed faster than they can be replaced. The loss of red blood cells ...